Novel anionic microparticles are a potent adjuvant for the induction of cytotoxic T lymphocytes against recombinant p55 gag from HIV-1

Journal of Controlled Release

Volumn 67, Issue 2-3, 2000, Pages 347-356

  Kazzaz, J ^a   Neidleman, J ^a   Singh, M ^a   Ott, G ^a   O'Hagan D T ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Adjuvant; Cytotoxic T lymphocytes; HIV 1; Microparticles; Vaccine

Indexed keywords

ADJUVANT; DODECYL SULFATE SODIUM; GAG PROTEIN; MICROSPHERE; NEUTRALIZING ANTIBODY; POLYGLACTIN; PROTEIN P55; RECOMBINANT PROTEIN; VIRUS VACCINE;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG FORMULATION; DRUG MANUFACTURE; ENCAPSULATION; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNIZATION; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TECHNIQUE; ZETA POTENTIAL;

ADJUVANTS, IMMUNOLOGIC; ADSORPTION; ANIMALS; ANIONS; CELL LINE; FEMALE; FIBROBLASTS; GENE PRODUCTS, GAG; INJECTIONS, INTRAMUSCULAR; KINETICS; MICE; MICE, INBRED STRAINS; MICROSPHERES; PARTICLE SIZE; PROTEIN PRECURSORS; RECOMBINANT PROTEINS; SODIUM DODECYL SULFATE; SURFACE-ACTIVE AGENTS; T-LYMPHOCYTES, CYTOTOXIC; THERMODYNAMICS;

EID: 0034601242     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-3659(00)00226-1     Document Type: Article

References (30)

1. Hilleman M.R. A simplified vaccinologists' vaccinology and the pursuit of a vaccine against AIDS. Vaccine. 16:1998;778-793.
2. Shibata R., Igarashi T., Haigwood N., Buckler-White A., Ogert R., Ross W., et al. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat. Med. 5:1999;204-210.
3. Igarashi T., Brown C., Azadegan A., Haigwood N., Dimitrov D., Martin M.A., et al. Human immunodeficiency virus type 1 neutralizing antibodies accelerate clearance of cell-free virions from blood plasma. Nat. Med. 5:1999;211-216.
4. Koup R.A., Safrit J.T., Cao Y., Andrews C.A., McLeod G., Borkowsky W., et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68:1994;4650-4655.
5. + cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J. Virol. 68:1994;6103-6110.
6. Musey L., Hughes J., Schacker T., Shea T., Corey L., McElrath M.J. Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection. N. Engl. J. Med. 337:1997;1267-1274.
7. Ogg G.S., Jin X., Bonhoeffer S., Dunbar P.R., Nowak M.A., Monard S., et al. Quantitation of HIV-1 specific cytotoxic lymphocytes and plasma load of viral RNA. Science. 279:1998;2103-2106.
8. Brodie S.J., Lewinsohn D.A., Patterson B.K., Jiyamapa D., Krieger J., Corey L., et al. In vivo migration and function of transferred HIV-1-specific cytotoxic T cells. Nat. Med. 5:1999;34-41.
9. Baba T.W., Liska V., Khimani A.H., Ray N.B., Dailey P.J., Penninck D., et al. Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques. Nat. Med. 5:1999;194-203.
10. Gupta R.K., Siber G.R. Adjuvants for human vaccines - current status, problems and future prospects. Vaccine. 13:1995;1263-1276.
11. Gupta R.K., Rost B.E., Relyveld E., Siber G.R. Adjuvant properties of aluminum and calcium compounds. Powell M.F., Newman M.J. Vaccine Design: The Subunit and Adjuvant Approach. 1995;229-248 Plenum Press, New York.
12. O'Hagan D.T. Recent advances in vaccine adjuvants for systemic and mucosal administration. J. Pharm. Pharmacol. 59:1998;1-10.
13. O'Hagan D.T., Rahman D., McGee J.P., Jeffery H., Davies M.C., Williams P., et al. Biodegradable microparticles as controlled release antigen delivery systems. Immunology. 73:1991;239-242.
14. Eldridge J.H., Staas J.K., Meulbroek J.A., Tice T.R., Gilley R.M. Biodegradable and biocompatible poly (D, L-lactide-co-glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies. Infect. Immun. 59:1991;2978-2986.
15. O'Hagan D.T., Jeffery H., Davis S.S. Long-term antibody responses in mice following subcutaneous immunization with ovalbumin entrapped in biodegradable microparticles. Vaccine. 11:1993;965-969.
16. Okada H., Toguchi H. Biodegradable microspheres in drug delivery. Crit. Rev. Ther. Drug Car. Sys. 12:1995;1-99.
17. O'Hagan D.T., Singh M., Gupta R.K. Poly(lactide-co-glycolide) microparticles for the development of single-dose controlled-release vaccines. Adv. Drug Del. Rev. 32:1998;225-246.
18. Singh M., Carlson J.R., Briones M., Ugozzoli M., Kazzaz J., Barackman J., et al. A comparison of biodegradable microparticles and MF59 as systemic adjuvants for recombinant gD from HSV-2. Vaccine. 16:1998;1822-1827.
19. Maloy K.J., Donachie D.T., O'Hagan D.T., Mowat M.A. Induction of mucosal and systemic immune responses by immunization with ovalbumin entrapped in poly(lactide-co-glycolide) microparticles. Immunology. 81:1994;661-667.
20. + Th1 cells. Vaccine. 113:1995;1741-1749.
21. O'Hagan D.T. The prospects for the development of new and improved vaccines through the use of microencapsulation technology. Levine M.M., Woodrow G.C., Kaper J.B., Cobon G.S. New Generation Vaccines. 2nd Edition:1997;215-228 Marcel Dekker, Inc. Chapter 17.
22. Waite J.H., Wang C.Y. Spectrophotometric measurement of dodecyl sulfate with basic fuchsin. Anal. Biochem. 70:1976;279-280.
23. Doe B., Steimer K.S., Walker C.M. Induction of HIV-1 envelope (gp120)-specific cytotoxic T lymphocyte responses in mice by recombinant CHO-derived gp120 is enhanced by enzymatic removal of N-linked glycans. Euro. J. Immunol. 24:1994;2369-2376.
24. Mark A., Carlsson R.-M., Granstrom M. Subcutaneous versus intramuscular injection for booster DT vaccination of adolescents. Vaccine. 17:1999;2067-2072.
25. Brown L., Munoz C., Siemer L., Edelman E., Langer R. Controlled release of insulin from polymer matrices. Control of diabetes in rats. Diabetes. 35:1986;692-697.
26. Johnson R.E., Lanaski L.A., Gupta V., Griffin M.J., Gaud H.T., Needham T.E., et al. Stability of atriopeptin III in poly(lactide-co-glycolide) microparticles. J. Control. Rel. 17:1991;61.
27. Park T.G., Lu W., Crotts G. Importance of in vitro experimental conditions on protein release kinetics, stability and polymer degradation in protein encapsulated poly (D, L-lactic acid-co-glycolic acid) microspheres. J. Control. Rel. 33:1995;211.
28. Shenderova A., Burke T.G., Schwendeman S.P. The acidic microclimate in poly(lactide-co-glycolide) microspheres stabilizes camptothecins. Pharm. Res. 16:1999;241-248.
29. Montanari L., Costantini M., Signoretti E.C., Valvo L., Santucci M., Bartolomei M., et al. Gamma irradiation effects on poly(D, L-lactictide-co-glycolide) microspheres. J. Control. Rel. 56:1998;219-229.
30. Singh M., Briones M., Ott G., O'Hagan D.T. Cationic microparticles: A potent delivery system for DNA vaccines. Proc. Natl. Acad. Sci. USA. 97:2000;811-816.